Celadon has also received several expressions of interest in the sale of its pharmaceutical-grade product. The firm says it is currently in discussions to convert these into commercial contracts. James Short, Founder and Chief Executive Officer of Celadon said: "We are delighted to have secured the £7 million credit facility at such an important time in the Company's growth journey. It will support the growth in our operations to meet the increasing demand for Celadon's product. "With the flexibility that the facility brings to the Group, we continue to confidently pursue the conversion of expressions of interest for Celadon's product into formal sale contracts, and build out the underlying operations required to deliver them."